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Abstract 
Pseudoenzymes were first described more than 50 years ago, when it was 
recognised that a subset of proteins that are structurally homologous to active 
enzymes lack amino acids necessary for catalytic activity. Recently, interest in 
pseudoenzymes has surged as it has become apparent that they constitute ~10% of 
proteomes and perform essential metabolic and signalling functions that can be 
experimentally distinguished from catalytic outputs of enzymes. Here, we highlight 
recent structural studies of pseudoenzymes, which have revealed the molecular 
basis for roles as allosteric regulators of conventional enzymes, as molecular 
switches and integrators, as hubs for assembling protein complexes, and as 
competitors of substrate availability and holoenzyme assembly. As structural studies 
continue to illuminate pseudoenzyme molecular mechanisms, we anticipate that our 
knowledge of the breadth of their biological functions will expand in parallel. 
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Introduction 
Genomic sequencing of many organisms confirms that nearly all enzyme families 
include pseudoenzyme homologues, which are predicted to be enzymatically inactive 
due to the loss of key catalytic amino acid residues. Pseudoenzymes are already 
known to be conserved in ~20 different protein families [1], including well-studied 
examples of pseudokinases, pseudophosphatases and pseudoproteases [2-6]. In 
these families, incremental changes in catalytic and substrate-binding sites created 
new evolutionary trajectories that led to the evolution of pseudoenzymes from 
enzyme templates sharing a similar fold [7,8]. Although an absence of conserved 
catalytic residues is not proof of catalytic deficiency, very high sequence and/or 
structural conservation suggests that pseudoenzymes have been functionally 
selected across all branches of life, and preserved to regulate cell biology in a 
catalytically-independent manner. Although pseudoenzymes comprise a significant 
percentage of proteomes, we understand little about individual classes relative to 
their enzyme counterparts. However, since much of what we know about 
pseudoenzymes arose from structural studies, and the fold of proteins provides clues 
to functions, this review will focus on key examples that help illustrate the general 
pseudoenzyme principles underlying specialised non-catalytic functions.  
 
Four classes of biological pseudoenzyme mechanism  
In terms of predicted and known mechanisms, pseudoenzymes fall into four major 
classes (Figure 1). The first of these, for which a number of examples are known in 
the protein kinase, phosphatase and ubiquitination fields, still retain enzyme-like 
architecture, but have evolved an ability to regulate a catalytically active partner that 
generates a biological output in signalling or metabolism (Figure 1a). The second 
class acts as “switches” that integrate signals in the form of post-translational 
modifications or binding to metabolic ligands, which trigger interconversion between 
inactive and active conformations (Figure 1b). The third category appears to have 
gained new functions as protein interaction modules through structural specialisation, 
where they can act as cellular scaffolds to nucleate the assembly of protein 
complexes or regulate the localization or trafficking of a binding partner (Figure 1c). 
The fourth category has repurposed canonical features of a protein fold that is shared 
with active enzyme relatives to act as competitors for either substrate binding (as 
catalytic ‘traps’) or higher order complex assembly (Figure 1d). 
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How has structure illuminated the molecular mechanisms of pseudoenzymes? 
Building upon a flood of genomic data, structural studies have provided key insights 
into the mechanisms by which pseudoenzymes operate as protein (and ligand) 
interaction domains to elicit biological responses. Additionally, pseudoenzyme 
structures have been instrumental in clarifying the molecular basis for deficient 
catalytic activity, whether it be: loss of canonical catalytic residues; loss of cofactor 
binding; loss of allosteric regulatory potential; occlusion of the active site by 
sequences divergent from those in an active enzyme counterpart; or active site 
blockade by non-canonical appendages. Importantly, while conventional enzymes 
are best understood for their catalytic functions, structural studies of pseudoenzymes 
are also providing an avenue to help understand non-catalytic functions of 
catalytically active enzymes, and in so-doing, are uncovering new strategies for 
therapeutic intervention. 
 
1. Allosteric Activators 
A conceptually simple mechanism that helps explain the prevalence of 
pseudoenzymes in biology is the finding that, upon binding, a pseudoenzyme can 
often impact a conventional enzyme’s activity. The best characterised examples of 
such allostery involve pseudoenzymes regulating a structurally-related enzyme 
counterpart, as exemplified by several pseudokinases (Figure 2a) [9-13], and the 
regulation of the protease Caspase-8 by the pseudoprotease FLIP (Figure 2b) [14]. 
Multiple cases of domain duplication have led to tandem pseudoenzyme-enzyme 
domain architectures within the same polypeptide—for example, kinases like JAK1-3 
and TYK2 (Figure 2a), the ATPase EccC (addressed in scaffolds section below) and 
the GTPase p190RhoGAP—in which a pseudoenzyme fold is sandwiched between 
neighbouring catalytic GTPase and GAP domains. 
 
Further examples of allosteric regulation between inactive and active enzyme 
homologues lie in the ubiquitin system, particularly the Really Interesting New Gene 
(RING) proteins that comprise the largest class of ubiquitin ligase. There are 
numerous examples of RING heterodimers where one component has a functional 
binding site for a ubiquitin-conjugating (E2) enzyme, and one inactive RING cannot 
bind E2. Perhaps the best known is MDM2-MDMX, where the active RING MDM2 
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can form a functional complex with MDMX to promote ubiquitination of p53. MDMX 
plays this role because it retains a conserved C-terminal hydrophobic residue present 
in active RINGs, which is essential for stabilisation of the catalytic complex [15]. 
Additional examples include the BRCA1–BARD1 RING complex [16]; and Polycomb 
Repressive Complexes (Figure 2c), where an active RING1a/b component is able to 
partner with one of 6 different PCGF inactive RINGs (PCGF1–6). In addition to 
stabilising the catalytic complex, varying pseudoenzyme PCGF RINGs participate in 
substrate recognition and can modulate the intrinsic catalytic rate of their respective 
complexes [17,18]. On the flip-side to ubiquitin conjugation by RINGs, ubiquitin 
removal by the BRCC36 deubiquitinase is controlled by pseudoDUBs of the 
KIAA0157 family. KIAA0157 is essential for assembly of a heterotetrameric BRC366–
KIAA0157 complex, in which BRC366 becomes catalytically active and the catalytic 
sites of BRC366 are ideally arranged to act upon their preferred Lys63-linked ubiquitin 
substrate (Figure 2d; [19]). 
The frequency of pseudoenzymes regulating structurally-similar enzymes has 
been proposed to arise from gene duplications that liberate the second gene from 
selective pressures that normally ensure it catalyzes a chemical reaction, therefore 
encouraging regulatory specialisation [7,8]. Interestingly, many enzymes are now 
appreciated to possess ‘pseudoenzyme’ modes of allostery, where the catalytic 
potential of the enzyme is overridden in favour of a pseudoenzyme-like 
conformational output for a biological function. Examples include a non-enzyme 
scaffolding function of Caspase-8 in the immune system [20], and a non-catalytic 
function for the conformationally-flexible canonical kinase Aurora A as an N-Myc 
regulator in neuroblastoma [21].  
 
2. Signal integrators/molecular switches 
Modification of, or ligand binding to, pseudoenzymes can enable them to act as 
“receivers” of information from upstream regulators to control a downstream output. 
Structural and biochemical studies of the nucleotide-binding pseudokinase, Mixed 
lineage kinase domain-like (MLKL; Figure 3a), are illustrative of how post-
translational modification, in this case phosphorylation of the pseudokinase domain 
activation loop by the upstream activator kinase, RIPK3, can toggle a molecular 
switch to induce a downstream effector function [22,23]. MLKL phosphorylation is 
proposed to induce a conformational change in the pseudokinase domain that 
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relieves a suppressive interaction between the pseudokinase domain and the N-
terminal four-helix bundle domain (Figure 3a). Release of the latter permits MLKL 
oligomerisation, membrane translocation and death of a cell by the regulated death 
pathway, necroptosis [24].  
In addition to covalent modifications, molecular switch functions could 
analogously be imparted upon ligand binding to pseudoenzymes. Structural studies 
of ADCK3 (COQ8A), considered a pseudokinase because of a contorted active site 
that confers a preference for ADP over ATP [25], have revealed the importance of 
nucleotide binding to its function. While precise details are still emerging, nucleotide 
binding to ADCK3 promotes assembly of a functional Coenyzme Q biosynthetic 
holoenzyme and, furthermore, induces conformational changes that expose putative 
lipid binding pockets adjacent to the substrate-occluding N-terminal helices (Figure 
3b; [26]).  
Ligand binding has also been shown to exert subtle switching effects on 
pseudoenzymes that are not always clear from crystal structures. In the case of 
RNaseL, binding of nucleotide to the pseudokinase domain and/or the cyclic 
nucleotide second messenger, 2′,5′-oligoadenylate (2-5A), to a channel between the 
N-terminal ankyrin repeat and pseudokinase domains promotes activity of the C-
terminal nuclease domains within the RNaseL homodimer (Figure 3c; [27]). Because 
apo and ligand-bound crystal structures are not obviously different, based on solution 
scattering data it was proposed that the role of nucleotide binding was to lock the 
pseudokinase domain into a closed conformation to facilitate nuclease activity [27]. 
These data suggest that ATP binding by the related Ire1, which contains a 
conventional protein kinase domain rather than a pseudokinase domain [28], may 
similarly serve a conformational role to augment nuclease activity. While these 
examples are illustrative of the propensity of some pseudoenzyme functions to be 
tuned by modification or ligand binding, not all pseudoenzymes are expected to 
undergo conformational switching; biochemical studies suggest that fewer than half 
of all pseudokinases retain binding to conventional nucleotides [29,30].  
 
3. Scaffolds for assembly of protein complexes  
Several multimeric complex structures have provided insights into how 
pseudoenzymes assemble more than one partner simultaneously to create higher 
order scaffolds or “hubs”. The pseudokinase PAN3 provides an interesting case in 
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point. PAN3 forms an asymmetric dimer [31], which scaffolds the assembly of a 
higher order complex with the mRNA deadenylation enzyme, PAN2, which itself 
contains a pseudo-ubiquitin C-terminal hydrolase (UCH) domain (Figure 3d). Beyond 
simply scaffolding complex formation, PAN3 abuts the PAN2 RNase domain within 
the complex and promotes RNase activity, whilst the pseudokinase ATP-binding site 
recruits poly(A) substrates to the holoenzyme [32].  
The Tribbles (TRIB) family of proteins (and the homolog SgK495/STK40) also 
employ an atypical pseudokinase domain to bring a catalytic enzyme into proximity of 
its substrate. In this case, a ternary complex is formed between TRIB1, COP1 
ubiquitin ligase and the C/EBP substrate, which is appropriately positioned for 
ubiquitination [29,33,34]. The structure of TRIB1 has demonstrated that its C-terminal 
tail, which binds COP1, can also self-associate with the pseudokinase domain in cis 
[29], likely through a mutually exclusive mechanism (Figure 3e; [35]). While the 
structural mechanism is still not clear, it appears that formation of a Substrate–
TRIB1–COP1 holocomplex must involve an evolutionary imprinted conformational 
change in the TRIB1 pseudokinase, which is likely conserved in all eukaryotic 
Tribbles proteins [32]. Another pseudokinase, KSR2, serves as a hub to orchestrate 
Raf communication with the effector kinase, MEK1. KSR2 is able to activate the RAF 
kinases via a “back-to-back” dimer interface (Figure 2a), but also bind to MEK1 
through a “face-to-face” interaction to promote phosphorylation of MEK1 by RAF [36]. 
In some cases, including the EccC family of hexameric ATPases (see below) 
and the RBR ubiquitin ligases, pseudoenzyme domains are embedded in the context 
of tandem arrays with conventional enzyme counterparts, where they have evolved 
dual functions as both hubs and as allosteric regulators. In RBR ubiquitin ligases, a 
benign-catalytic region that lacks a catalytic cysteine residue (BRcat; also known as 
IBR for in-between-RING), lies adjacent to a catalytic RBR RING domain, [37]. 
Structures of autoinhibited and active RBR ligases (Parkin and HOIP, respectively) 
have demonstrated important roles that BRcat plays in each state. In inactive Parkin, 
the BRcat stabilises an autoinhibited conformation that blocks the active site, 
whereas in active HOIP the BRcat contacts the E2-Ub conjugate and binds an 
additional ubiquitin that stabilises the catalytically competent complex [38-40].    
The EccC protein, a type VII secretion ATPase of bacterial pathogens, is 
composed of an array of three linked ATPase domains, two of which are 
pseudoenzymes lacking Walker A Glu residues, permitting them to bind, but not 
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hydrolyse ATP (Figure 3f; [41]). EsxB, a secreted substrate of EccC, is instrumental 
in the ordered assembly and activation of the active complex. EsxB binding by the 
terminal pseudoATPase domain simultaneously promotes release of autoinhibition 
between the ATPase domain and central pseudoATPase, and drives multimerization 
and activation of the hexameric holoenzyme (Figure 3f; [41]). 
PseudoGTPases are particularly abundant throughout nature [1], and 
structural insights into their scaffolding and allosteric functions are eagerly awaited. 
Such structures are already proving important to enhance our understanding of how 
pseudoGTPases such as the kinetochore-regulating scaffold CENP-M, which is 
unable to bind GTP, functions to assemble and regulate a multi-protein complex that 
recruits CENP-T/W proteins to the kinetochores of metazoan chromosomes [42]. 
 
4. Competition for substrate or enzyme binding 
Lastly, examples of pseudoenzymes that act as competitors in various guises have 
been identified (Figure 4). The structural capacity of some pseudoenzymes to 
sequester substrates is vividly illustrated by the pseudo-chitinase YKL-39 (Figure 4a; 
[43,44]). YKL-39 lacks the essential Glu within the DxxDxDxE catalytic motif, 
meaning the protein can bind chito-oligosaccharides with a nanomolar affinity, but not 
hydrolyse them, and thus sequester them away from catalytically-active counterparts 
(or immunological receptors) to prevent processing. Although structures are yet to be 
reported, another competitive mode of action is illustrated by pseudophosphatases 
(Figure 4b), which bind substrates with high affinity to antagonize conventional 
enzymes. In the case of the pseudophosphatases, EGG-4 and EGG-5, interaction 
with the phosphorylated activation loop of the protein kinase MBK-2 prevents 
regulatory dephosphorylation [45,46]. A related mode of action is exemplified by the 
pseudophosphatase STYX, which has been shown to compete with the dual-
specificity phosphatase DUSP4 for binding to the canonical protein kinases, ERK1 
and ERK2 [47]. As a result, STYX binding precludes DUSP4 engagement and 
ERK1/2 dephosphorylation and inactivation, which is likely to be important in cells, 
where compartmentalization of the ERK module regulates transforming potential [48]. 
Because these substrate “traps” could evolve from simple loss of catalytic functions, 
we anticipate this group is abundant in nature. This idea is supported by the 
impressive array of pseudophosphatase domains within the myotubularin and 
receptor tyrosine phosphatase families in higher eukaryotes [5]. 
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In addition to substrate competition, enzyme sequestration represents another 
mode of pseudoenzyme action. This is exemplified by a naturally-occurring, 
catalytically-defective variant of aldehyde dehydrogenase-2 (ALDH2), termed 
ALDH2*2, which can compete with the catalytically-active counterpart, ALDH2*1, to 
‘poison’ complex assembly into an active homo-tetramer, thus inhibiting activity 
(Figure 4c; [49]). 
 
Conclusions 
In this review, we have sought to illustrate the diversity of mechanisms underlying 
pseudoenzyme functions as revealed from recent structural studies. An underlying 
theme is that pseudoenzymes behave as protein interaction modules, whether in the 
guise of allosteric regulators, signal integrators, nucleators of protein complex 
assembly or as substrate competitors with conventional enzymes. It is also becoming 
clear that pseudoenzymes can often perform several of these functions 
simultaneously. We expect that future multidisciplinary studies will reveal new and 
unexpected modes of action of pseudoenzymes, which will in turn expand knowledge 
of the repertoire of non-catalytic functions that may be performed by conventional 
enzymes. 
 
 
  
! 9 
Acknowledgements 
JMM thanks the National Health and Medical Research Council of Australia for 
supporting work in this field in his laboratory (1105754, 1057905, 1067289, 1124735, 
1124737; IRIISS 9000220), and the Victorian State Government Operational 
Infrastructure Support. PDM appreciates support of research in this field from the 
Health Research Council of New Zealand and a Rutherford Discovery Fellowship 
from the New Zealand government administered by the Royal Society of New 
Zealand.  PAE acknowledges support from The Royal Society, North West Cancer 
Research (CR1037) and a BBSRC tools and technology grant (BB/N021703/1).  We 
apologize to colleagues whose work we were unable to cite due to space constraints. 
 
  
! 10 
References 
1. Murphy JM, Farhan H, Eyers PA: Bio-zombie: the rise of pseudoenzymes in 
biology. Biochem Soc Trans 2017, In press. 
•• A description of the ~20 different classes of pseudoenzymes identified to date and 
their functions in biology. 
2. Adrain C, Freeman M: New lives for old: evolution of pseudoenzyme function 
illustrated by iRhoms. Nat Rev Mol Cell Biol 2012, 13:489-498. 
3. Eyers PA, Murphy JM: The evolving world of pseudoenzymes: proteins, 
prejudice and zombies. BMC Biol 2016, 14:98. 
•An overview of the rapidly emerging pseudoenzyme field. 
4. Jacobsen AV, Murphy JM: The secret life of kinases: insights into non-
catalytic signalling functions from pseudokinases. Biochem Soc Trans 
2017, Submitted. 
5. Reiterer V, Eyers PA, Farhan H: Day of the dead: pseudokinases and 
pseudophosphatases in physiology and disease. Trends Cell Biol 2014, 
24:489-505. 
6. Eyers PA, Murphy JM: Dawn of the dead: protein pseudokinases signal new 
adventures in cell biology. Biochemical Society Transactions 2013, 41:969-
974. 
7. Pils B, Schultz J: Inactive enzyme-homologues find new function in regulatory 
processes. J Mol Biol 2004, 340:399-404. 
8. Todd AE, Orengo CA, Thornton JM: Sequence and structural differences 
between enzyme and nonenzyme homologs. Structure 2002, 10:1435-1451. 
9. Littlefield P, Liu L, Mysore V, Shan Y, Shaw DE, Jura N: Structural analysis of 
the EGFR/HER3 heterodimer reveals the molecular basis for activating 
HER3 mutations. Sci Signal 2014, 7:ra114. 
•Illustration of pseudoenzyme allostery describing how HER3 activates the EGFR 
kinase. 
10. Lupardus PJ, Ultsch M, Wallweber H, Bir Kohli P, Johnson AR, Eigenbrot C: 
Structure of the pseudokinase-kinase domains from protein kinase TYK2 
reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc Natl 
Acad Sci U S A 2014, 111:8025-8030. 
•The first crystal structure of the tandem pseudokinase-kinase domains from a JAK 
family member. 
11. Rajakulendran T, Sahmi M, Lefrancois M, Sicheri F, Therrien M: A dimerization-
dependent mechanism drives RAF catalytic activation. Nature 2009, 
461:542-545. 
12. Zeqiraj E, Filippi BM, Goldie S, Navratilova I, Boudeau J, Deak M, Alessi DR, van 
Aalten DM: ATP and MO25alpha regulate the conformational state of the 
STRADalpha pseudokinase and activation of the LKB1 tumour 
suppressor. PLoS Biol 2009, 7:e1000126. 
13. Zeqiraj E, Filippi BM, Deak M, Alessi DR, van Aalten DM: Structure of the 
LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase 
activation. Science 2009, 326:1707-1711. 
14. Yu JW, Jeffrey PD, Shi Y: Mechanism of procaspase-8 activation by c-FLIPL. 
Proc Natl Acad Sci U S A 2009, 106:8169-8174. 
15. Linke K, Mace PD, Smith CA, Vaux DL, Silke J, Day CL: Structure of the 
MDM2/MDMX RING domain heterodimer reveals dimerization is required 
for their ubiquitylation in trans. Cell Death Differ 2008, 15:841-848. 
! 11 
16. Brzovic PS, Rajagopal P, Hoyt DW, King MC, Klevit RE: Structure of a BRCA1-
BARD1 heterodimeric RING-RING complex. Nat Struct Biol 2001, 8:833-
837. 
17. McGinty RK, Henrici RC, Tan S: Crystal structure of the PRC1 ubiquitylation 
module bound to the nucleosome. Nature 2014, 514:591-596. 
18. Taherbhoy AM, Huang OW, Cochran AG: BMI1-RING1B is an autoinhibited 
RING E3 ubiquitin ligase. Nat Commun 2015, 6:7621. 
19. Zeqiraj E, Tian L, Piggott CA, Pillon MC, Duffy NM, Ceccarelli DF, Keszei AF, 
Lorenzen K, Kurinov I, Orlicky S, et al.: Higher-Order Assembly of BRCC36-
KIAA0157 Is Required for DUB Activity and Biological Function. Mol Cell 
2015, 59:970-983. 
••First structure of a pseudoDUB (KIAA0157), revealing allosteric and hub functions 
that organize and activate BRCC36 DUB activity in higher order complexes 
20. Henry CM, Martin SJ: Caspase-8 Acts in a Non-enzymatic Role as a Scaffold 
for Assembly of a Pro-inflammatory "FADDosome" Complex upon TRAIL 
Stimulation. Mol Cell 2017, 65:715-729 e715. 
21. Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N, Kenney AM, 
Schulte JH, Beijersbergen R, Christiansen H, et al.: Stabilization of N-Myc is 
a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009, 
15:67-78. 
22. Murphy JM, Czabotar PE, Hildebrand JM, Lucet IS, Zhang JG, Alvarez-Diaz S, 
Lewis R, Lalaoui N, Metcalf D, Webb AI, et al.: The pseudokinase MLKL 
mediates necroptosis via a molecular switch mechanism. Immunity 2013, 
39:443-453. 
23. Petrie EJ, Hildebrand JM, Murphy JM: Insane in the membrane: a structural 
perspective of MLKL function in necroptosis. Immunol Cell Biol 2017, 
95:152-159. 
24. Hildebrand JM, Tanzer MC, Lucet IS, Young SN, Spall SK, Sharma P, Pierotti C, 
Garnier JM, Dobson RC, Webb AI, et al.: Activation of the pseudokinase 
MLKL unleashes the four-helix bundle domain to induce membrane 
localization and necroptotic cell death. Proc Natl Acad Sci U S A 2014, 
111:15072-15077. 
•With reference 19, proposes a role for the MLKL pseudokinase domain, both as a 
molecular switch and as an interaction domain that suppresses executioner 
domain activity 
25. Stefely JA, Reidenbach AG, Ulbrich A, Oruganty K, Floyd BJ, Jochem A, 
Saunders JM, Johnson IE, Minogue CE, Wrobel RL, et al.: Mitochondrial 
ADCK3 employs an atypical protein kinase-like fold to enable coenzyme 
Q biosynthesis. Mol Cell 2015, 57:83-94. 
26. Stefely JA, Licitra F, Laredj L, Reidenbach AG, Kemmerer ZA, Grangeray A, 
Jaeg-Ehret T, Minogue CE, Ulbrich A, Hutchins PD, et al.: Cerebellar Ataxia 
and Coenzyme Q Deficiency through Loss of Unorthodox Kinase Activity. 
Mol Cell 2016, 63:608-620. 
27. Huang H, Zeqiraj E, Dong B, Jha BK, Duffy NM, Orlicky S, Thevakumaran N, 
Talukdar M, Pillon MC, Ceccarelli DF, et al.: Dimeric structure of 
pseudokinase RNase L bound to 2-5A reveals a basis for interferon-
induced antiviral activity. Mol Cell 2014, 53:221-234. 
••ATP binding by the RNase L pseudokinase domain is proposed to promote activity 
of the adjacent RNase domain by locking the structure. 
! 12 
28. Lee KP, Dey M, Neculai D, Cao C, Dever TE, Sicheri F: Structure of the dual 
enzyme Ire1 reveals the basis for catalysis and regulation in 
nonconventional RNA splicing. Cell 2008, 132:89-100. 
29. Murphy JM, Nakatani Y, Jamieson SA, Dai W, Lucet IS, Mace PD: Molecular 
Mechanism of CCAAT-Enhancer Binding Protein Recruitment by the 
TRIB1 Pseudokinase. Structure 2015, 23:2111-2121. 
••The first structure of a Tribbles family pseudokinase providing important insights 
into the molecular basis for its scaffolding function. 
30. Murphy JM, Zhang Q, Young SN, Reese ML, Bailey FP, Eyers PA, Ungureanu D, 
Hammaren H, Silvennoinen O, Varghese LN, et al.: A robust methodology 
to subclassify pseudokinases based on their nucleotide-binding 
properties. Biochem J 2014, 457:323-334. 
•Approximately half of 31 pseudokinases surveyed did not bind to nucleotides, 
indicating they predominantly function as protein interaction modules. 
31. Christie M, Boland A, Huntzinger E, Weichenrieder O, Izaurralde E: Structure of 
the PAN3 pseudokinase reveals the basis for interactions with the PAN2 
deadenylase and the GW182 proteins. Mol Cell 2013, 51:360-373. 
32. Schafer IB, Rode M, Bonneau F, Schussler S, Conti E: The structure of the 
Pan2-Pan3 core complex reveals cross-talk between deadenylase and 
pseudokinase. Nat Struct Mol Biol 2014, 21:591-598. 
••With reference 29, structural delineation of how an asymmetric dimer of the 
pseudokinase PAN3 nucleates assembly of the deadenylation complex with 
the pseudoUCH domain-containing PAN2. 
33. Durzynska I, Xu X, Adelmant G, Ficarro SB, Marto JA, Sliz P, Uljon S, Blacklow 
SC: STK40 Is a Pseudokinase that Binds the E3 Ubiquitin Ligase COP1. 
Structure 2017, 25:287-294. 
34. Eyers PA, Keeshan K, Kannan N: Tribbles in the 21st Century: The Evolving 
Roles of Tribbles Pseudokinases in Biology and Disease. Trends Cell Biol 
2016, 10.1016/j.tcb.2016.11.002. 
35. Uljon S, Xu X, Durzynska I, Stein S, Adelmant G, Marto JA, Pear WS, Blacklow 
SC: Structural Basis for Substrate Selectivity of the E3 Ligase COP1. 
Structure 2016, 24:687-696. 
36. Brennan DF, Dar AC, Hertz NT, Chao WC, Burlingame AL, Shokat KM, Barford 
D: A Raf-induced allosteric transition of KSR stimulates phosphorylation 
of MEK. Nature 2011, 472:366-369. 
37. Spratt DE, Walden H, Shaw GS: RBR E3 ubiquitin ligases: new structures, 
new insights, new questions. Biochem J 2014, 458:421-437. 
38. Lechtenberg BC, Rajput A, Sanishvili R, Dobaczewska MK, Ware CF, Mace PD, 
Riedl SJ: Structure of a HOIP/E2~ubiquitin complex reveals RBR E3 
ligase mechanism and regulation. Nature 2016, 529:546-550. 
••First structure of an active RBR E3 ligase, in which the pseudoenzyme BRcat 
domain mediates E2~Ub contacts and Ub recruitment to the complex. 
39. Swatek KN, Komander D: Ubiquitin modifications. Cell Res 2016, 26:399-422. 
40. Trempe JF, Sauve V, Grenier K, Seirafi M, Tang MY, Menade M, Al-Abdul-Wahid 
S, Krett J, Wong K, Kozlov G, et al.: Structure of parkin reveals 
mechanisms for ubiquitin ligase activation. Science 2013, 340:1451-1455. 
41. Rosenberg OS, Dovala D, Li X, Connolly L, Bendebury A, Finer-Moore J, Holton 
J, Cheng Y, Stroud RM, Cox JS: Substrates Control Multimerization and 
Activation of the Multi-Domain ATPase Motor of Type VII Secretion. Cell 
2015, 161:501-512. 
! 13 
•Structures revealed the molecular basis for allosteric regulation of the ATPase 
domain by adjacent pseudoATPase domains, and their role in substrate 
recruitment and protein oligomerization. 
42. Basilico F, Maffini S, Weir JR, Prumbaum D, Rojas AM, Zimniak T, De Antoni A, 
Jeganathan S, Voss B, van Gerwen S, et al.: The pseudo GTPase CENP-M 
drives human kinetochore assembly. Elife 2014, 3:e02978. 
43. Ranok A, Wongsantichon J, Robinson RC, Suginta W: Structural and 
thermodynamic insights into chitooligosaccharide binding to human 
cartilage chitinase 3-like protein 2 (CHI3L2 or YKL-39). J Biol Chem 2015, 
290:2617-2629. 
•Insights into a pseudochitinase catalytic "trap" from structures bound to chito-
oligosaccharide ligands of different lengths. 
44. Schimpl M, Rush CL, Betou M, Eggleston IM, Recklies AD, van Aalten DM: 
Human YKL-39 is a pseudo-chitinase with retained chitooligosaccharide-
binding properties. Biochem J 2012, 446:149-157. 
45. Cheng KC, Klancer R, Singson A, Seydoux G: Regulation of MBK-2/DYRK by 
CDK-1 and the pseudophosphatases EGG-4 and EGG-5 during the 
oocyte-to-embryo transition. Cell 2009, 139:560-572. 
46. Parry JM, Velarde NV, Lefkovith AJ, Zegarek MH, Hang JS, Ohm J, Klancer R, 
Maruyama R, Druzhinina MK, Grant BD, et al.: EGG-4 and EGG-5 Link 
Events of the Oocyte-to-Embryo Transition with Meiotic Progression in C. 
elegans. Curr Biol 2009, 19:1752-1757. 
47. Reiterer V, Fey D, Kolch W, Kholodenko BN, Farhan H: Pseudophosphatase 
STYX modulates cell-fate decisions and cell migration by spatiotemporal 
regulation of ERK1/2. Proc Natl Acad Sci U S A 2013, 110:E2934-2943. 
48. Kidger AM, Rushworth LK, Stellzig J, Davidson J, Bryant CJ, Bayley C, Caddye E, 
Rogers T, Keyse SM, Caunt CJ: Dual-specificity phosphatase 5 controls 
the localized inhibition, propagation, and transforming potential of ERK 
signaling. Proc Natl Acad Sci U S A 2017, 114:E317-E326. 
49. Larson HN, Weiner H, Hurley TD: Disruption of the coenzyme binding site 
and dimer interface revealed in the crystal structure of mitochondrial 
aldehyde dehydrogenase "Asian" variant. J Biol Chem 2005, 280:30550-
30556. 
50. Dhawan NS, Scopton AP, Dar AC: Small molecule stabilization of the KSR 
inactive state antagonizes oncogenic Ras signalling. Nature 2016, 
537:112-116. 
51. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, 
Zhang Y, Habets G, et al.: Clinical efficacy of a RAF inhibitor needs broad 
target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599. 
52. Plechanovova A, Jaffray EG, Tatham MH, Naismith JH, Hay RT: Structure of a 
RING E3 ligase and ubiquitin-loaded E2 primed for catalysis. Nature 2012, 
489:115-120. 
53. Sato Y, Yoshikawa A, Yamagata A, Mimura H, Yamashita M, Ookata K, Nureki O, 
Iwai K, Komada M, Fukai S: Structural basis for specific cleavage of Lys 
63-linked polyubiquitin chains. Nature 2008, 455:358-362. 
54. Dong B, Silverman RH: Alternative function of a protein kinase homology 
domain in 2', 5'-oligoadenylate dependent RNase L. Nucleic Acids Res 
1999, 27:439-445. 
 
! 14 
 
  
! 15 
Figure Legends 
 
Figure 1. Modes of pseudoenzyme function 
Pseudoenzymes (green) exert their effects on signal transduction or metabolism 
through interactions with other proteins, including client enzymes (grey), or 
substrates (yellow).  
(a) Allosteric binding of a pseudoenzyme can positively or negatively regulate the 
catalytic activity of a conventional enzyme client.  
(b) Pseudoenzyme domains can act as receivers for post-translational modifications, 
such as (de)ubiquitylation, (de)phosphorylation or proteolytic cleavage, and can 
promote conformational switching and effector functions.  
(c) As protein interaction domains, pseudoenzymes can nucleate the assembly of 
protein complexes to bring enzyme and substrate pairs into proximity (top), or 
regulate protein localization, stability or quality control in a particular trafficking 
pathway or organelle (bottom).  
(d) Pseudoenzymes can compete with conventional enzymes to prevent assembly of 
higher order protein complexes (top), or sequester substrates to protect them from 
enzymatic processing (bottom). 
 
Figure 2. Allosteric regulation of active enzymes  
 
(a) Stabilisation of active kinases by pseudokinase partners. Shown are complexes 
between KSR–BRAF (based on superposition of KSR2 onto the BRAF homodimer; 
PDBs 5kkr and 3og7; [50] and [51] respectively), the crystal structure of HER3 
pseudokinase bound to the EGFR kinase domain (PDB 4riw; [9]), and the TYK2 
pseudokinase–kinase complex (PDB 4oli; [10]). PsK=pseudokinase, K=kinase. 
(b) Regulation of Caspase-8 activity by a pseudocaspase partner. Structure of the 
complex between proCaspase-8 (grey) and FLIP (green) (PDB 3h11; [14]). The 
intersubunit linker of Caspase-8, which undergoes proteolysis upon activation, is not 
visible in the crystal structure but is represented by a dotted line. 
(c) Active–inactive RING heterocomplexes regulate RING activity. Model of the 
putative RING1b-Bmi1–Histone–E2-Ub substrate complex, based on the structure 
from PDB 4r8p; [17]. Ubiquitin is modelled by superposition of primed E2-Ub 
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conjugate from PDB 4ap4; [52]. The non-E2 binding Bmi1 RING domain stabilises 
the E2-Ub conjugate in the closed conformation primed for attack by a substrate 
lysine from the histone substrate.  
(d) DUB regulation within a DUB-pseudoDUB complex. Structure of the complex 
between BRCC36 (grey surface) and the KIAA0157 pseudoDub (green cartoon) 
(PDB 5cw3; [19]).  A putative Lys63-linked Ub substrate is positioned by superposition 
into the active sites of BRC366 (based on PDB 2znv; [53]), which demonstrates the 
compatibility of the tetrameric BRCC36–KIAA0157 complex with its preferred 
substrate. 
 
Figure 3. Assembly of signalling complexes 
(a) The MLKL pseudokinase. MLKL is thought to exist in a basal state (left) where the 
N-terminal four-helix bundle domain is sequestered by the C-terminal pseudokinase 
domain (green). Upon phosphorylation of the pseudokinase domain activation loop, 
MLKL is proposed to undergo a conformational change (middle; PDB 4btf; [22]), 
leading to exposure of the four-helix bundle, oligomerisation, membrane 
translocation, permeabilisation of plasma membranes and cell death (right). 
(b) ADCK3 pseudokinase. The human mitochondrial UbiB pseudoenzyme ADCK3 is 
the first ancient UbiB protein kinase-like (PKL) family member to be characterised 
structurally [25,26], revealing UbiB-specific features that prevent canonical protein 
kinase activity (PDB 5i35). These include disintct N-terminal helical extensions that 
occlude the substrate-binding pocket (grey cartoon). 
 
(c) RNase L pseudokinase. RNase L is a homodimeric assembly containing ankyrin 
repeat domains linked to dual pseudokinase-ribonuclease domains. The 
pseudoenzyme domain (green) contains non-canonical adaptions in both N and C-
lobes, which prevent catalytic activity [54]. RNAse L drives the IFN-induced antiviral 
response in humans, and is activated by the 2,'5'-oligoadenylate (2-5A) second 
messenger, which binds in a cleft between the ankyrin repeats and pseudokinase 
domain. Crystal structures of RNase L (PDBs 4o1o and 4o1p) demonstrate how 2-5A 
and the pseudokinase region to drive the RNAse domain (yellow) into an enzyme 
conformation compatible with catalysis [27].  
(d) PseudoDUB and pseudokinase modules orient activity of the PAN2/3 complex. 
The PAN2/3 complex is shown with the dimer of PAN3 in cartoon representation, and 
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PAN2 as a surface (PDB 4q8j; [32]). The pseudokinase domains of PAN3 are shown 
in green, with the nucleotide-binding site (proposed to bind to polyA tails) indicated 
with spheres. The PseudoDUB domain of PAN2 (green) makes extensive contacts 
with the RNAse domain that contains the deadenylase active site (indicated with a 
black sphere).   
(e) Pseudokinase-based assembly of an E3-ligase complex. The C-terminal COP1-
binding motif of TRIB1 binds to the N-terminal lobe of the pseudokinase domain (left-
most structure, based on PDB 5cem [29]), but upon substrate binding must be 
dislodged from the pseudokinase domain to be recruited into a complex with the 
ubiquitin E3-ligase COP1 (right; TRIB1 tail–COP1 complex based on PDB 4igo [35]). 
Bound substrate is represented with a yellow line.  
(f) Oligomerisation of an active hexameric ATPase via pseudo-ATPase modules. 
EccC is comprised of an N-terminal active ATPase (grey) with two N-terminal 
pseudo-ATPase domains (green). The C-terminal pseudo-ATPase domain of EccC 
binds to peptides, which themselves emanate from dimeric substrates, and hence 
promote association of the active EccC ATPase hexamer [41]. 
 
Figure 4. Competition for substrate or enzyme binding 
(a) Sequestration of chito-oligosaccharides by the pseudochitinase, YKL-39. The 
crystal structure of YKL-39 has been solved bound to chito-oligosaccharides of 
varying residue length [43,44], the longest being polymeric GlcNAC6 (yellow) (PDB 
4p8x). 
(b) Pseudophosphatase binding to phosphorylated canonical kinases occludes 
conventional phosphatases. Left, binding of the pseudophosphatase, EGG-4 or 
EGG-5, shields the activation loop of the kinase MBK-2 from dephosphorylation 
[45,46]. Right, pseudophosphatase STYX regulates ERK activation by competing 
with the conventional phosphatase, DUSP4, for substrate binding [47]. 
(c) Pseudodehydrogenase can block assembly higher order enzyme or signalling 
complexes. Left, schematic of how the catalytically-defective variant, ALDH2*2, might 
compete with the active paralog, ALDH2*1, to prevent assembly of, and allosteric 
activation within, an ALDH2*1 homo-tetramer [49]. Right, homo-tetrameric structures 
of ALDH2*2 (green; PDB 1zum) and ALDH2*1 (grey; PDB 1nzz). 
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Highlights:
Pseudoenzymes are structural, but catalytically-defective, homologs of 
enzymes
Examples of pseudoenzymes have been identified in all kingdoms of life
Pseudoenzymes regulate metabolic and signalling enzymes and processes   
They function allosterically, as signal integrators, scaffolds, and competitors
Structural biology is helping to drive a ‘pseudoenzyme revolution’
